In early 2001, manufacturers of AIDS drugs were judged to prevent developing countries from violating its patents. This issue was due to the price. Developing countries can not afford market prices for these products. At the same time, pharmaceutical companies are reluctant to sell drugs at or below the cost in one country, and 10 to 20 times the value in the other country. Using a series of articles published, this case describes the pressures facing the pharmaceutical companies, and asks the question "How would they react?"
This case is only available in paper format (HBP do not have the rights to distribute digital content). As a result, a digital copy of an educator if not available through this Web site. "Hide
by John T. Gourville Source: Harvard Business School 14 pages. Publication Date: February 26, 2002. Prod. # 502 061-HCB-ENG
Related Case Solutions & Analyses:
Regulatory Uncertainty and Corporate Responses to Environmental Protection in China
SecondMarket – Providing Liquidity for Shareholders of Privately Held iContact
Systems Infrastructure at Google (B)
Bank of America-Merrill Lynch
CityCenter (C): Turmoil and Choices
Cocoa Petes Chocolate Adventures (Abridged)
Ahold versus Tesco DuPont Analysis
The Risk Management Foundation of the Harvard Medical Institutions, Inc.
Banff Aspen Lodge: Evolving the Business Strategy
Berkshire Partners: Bidding for Carter’s
